Lynne Chou left Kleiner Perkins Caufield & Byers (KPCB) in 2018 and started her own fund Define Ventures where she focuses on life science investing in medical devices, diagnostics, and digital health. She works alongside entrepreneurs to develop impactful technologies and therapies for improving patients’ lives.
Before joining KPCB, Lynne had over twelve years of healthcare operating and investing experience. Most recently, Lynne worked for eight years at Abbott Vascular and Guidant in multiple roles and worked on the launch of over ten interventional cardiology and cardiac surgery product families both in the US and internationally. Most recently, Lynne lead the global launch of Absorb, the world’s first bioresorbable vascular scaffold, recognized by Wall Street Journal as Medical Device Technology Innovation of the Year and Popular Mechanics. Lynne was responsible for building the global commercial strategy and therapy development as well as playing a key role in the clinical, reimbursement, operational strategy for the therapy. Earlier in her career, Lynne worked at Apax Partners with a focus on software venture capital investing. In addition, Lynne worked at Goldman Sachs in the Mergers and Acquisitions group and worked on multiple multi-billion dollar acquisitions and sell side transactions in various industries.
Lynne earned a bachelor of science degree in industrial engineering from Stanford University and an M.B.A. from Harvard Business School.
MEDIA ABOUT LYNNE CHOU